Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Pharmaceutical firm responds to call for acute radiation syndrome therapy for U.S. forces
February 27th, 2006
Hollis-Eden Pharmaceuticals, Inc., (HEPH) has responded to the Sources Sought Notice (SSN) from the Department of Defense (DOD) titled, "Seeking Sources in the Advanced Development of Medical Radiation Countermeasures." The company has also received a letter from the DOD indicating that it intends to issue a Request for Proposal (RFP) for medical radiation countermeasures in the first half of 2006 and that it highly encourages Hollis-Eden to respond to the RFP once issued. The SSN is the first step in this procurement process. The stated purpose of the SSN is to identify companies that believe they have viable candidate drugs that can be...
Source: Pharma Business Week (2006-02-27)
|
